Kite Pharma Inc (NASDAQ:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today …
Kite Pharma Inc (NASDAQ:KITE) announced that Steven A. Rosenberg, M.
Maxim analyst Jason McCarthy was out pounding the table on Kite Pharma Inc (NASDAQ:KITE) Thursday, reiterating a Buy rating and a price target of $87, which implies …
Kite Pharma, Inc. (NASDAQ:KITE) announced that Dr.
Kite Pharma Inc (NASDAQ:KITE) announced that it has expanded its collaboration with theNetherlands Cancer Institute (NKI). Kite and the NKI have entered into an …
Kite Pharma Inc (NASDAQ:KITE) announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending KTE-C19 …
In a research report released today, FBR Capital analyst Edward White initiated coverage on shares of Kite Pharma Inc (NASDAQ:KITE) with a price target of …
Recently, various executives have taken part in insider selling activity for the stocks of Intercept Pharmaceuticals Inc (NASDAQ:ICPT), Kite Pharma Inc (NASDAQ:KITE), Agios Pharmaceuticals Inc (NASDAQ:AGIO), and Pacira …
Regulatory Viewpoints The market punished Kite Pharma Inc (NASDAQ:KITE)’s shares during the first half of August selling off -30% from the close on …
In a research report issued Monday, Maxim Group analyst Jason McCarthy reiterated a Buy rating on shares of Kite Pharma Inc (NASDAQ:KITE) with a price …
